Comparative Pharmacology
Head-to-head clinical analysis: LANABIOTIC versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANABIOTIC versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
LANABIOTIC vs TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LANABIOTIC is a lantibiotic that inhibits bacterial cell wall synthesis by binding to lipid II, a key precursor in peptidoglycan biosynthesis, thereby disrupting cell wall integrity and causing cell death.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby inhibiting thymidine synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides in Gram-negative bacteria.
500 mg orally every 12 hours for 7-14 days.
One drop in each affected eye every 2 to 4 hours for 7 to 10 days.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
Trimethoprim: 8-10 hours (normal renal function); Polymyxin B: 6 hours (prolonged in renal impairment).
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-30%.
Trimethoprim: renal (80-90% unchanged, 10-20% metabolites); Polymyxin B: renal (60% unchanged, 40% nonrenal).
Category C
Category D/X
Antibiotic
Antibiotic